Amundi’s MoonLake Immunotherapeutics MLTX Stock Holding History

Amundi’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12	Closed	-$457	–	1981
2025 Q1	$457	Hold	12	–	–	﹤0.01%	2132
2024 Q4	$578	Buy	+12	New	+$613	﹤0.01%	2099

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Amundi's MLTX Position: Q2 2025 in Review

Amundi sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2025, closing a stake of 12 shares — an estimated $457 sold.

Amundi first reported a position in MLTX in Q4 2024 and held it in 2 quarters. The position peaked at $578 in Q4 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q2 2025.

Amundi reported no remaining MoonLake Immunotherapeutics position as of Q2 2025 after selling out during the quarter.
Amundi sold 12 MoonLake Immunotherapeutics shares in Q2 2025, an estimated $457.
Amundi first reported a position in MoonLake Immunotherapeutics in Q4 2024 and held it in 2 quarters.
Amundi's MoonLake Immunotherapeutics position peaked at $578 in Q4 2024.
130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.